The bladder cancer is a chemosensitive disease. Level I evidence supports neoadjuvant chemotherapy in the treatment
of invasive bladder cancer. Standard first-line therapy remains gemcitabine combined with cisplatin or methotrexate,
vinblastine, doxorubicin, and cisplatin (M-VAC). The second line of treatment with vinflunine, having superiority over
the best supportive care, has shown efficient in the trial phase III.